An observational study in Hip OA, sponsored by Meiji Pharma Spain S.A.. Recruiting at 4 sites in Spain. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2026-10-20.
Sponsored by Meiji Pharma Spain S.A. · Observational
The study population consists of approximately 40 adult outpatients aged 40 years or older with symptomatic hip osteoarthritis of at least 1 year of clinical evolution, treated with intra-articular hyaluronic acid in routine clinical practice within the Traumatology and Rehabilitation departments of participating hospitals in Spain.
642 studies on the registry are indexed under Osteoarthritis, Hip; 122 are open to participants now.
This study's planned enrollment of 40 is below the median of 135 across 159 observational studies indexed under Osteoarthritis, Hip.
Browse Osteoarthritis, Hip studies →Meiji Pharma Spain S.A. is the lead sponsor of 2 studies on the registry; 1 is open to participants now.
Counted across the registry records on this site, refreshed daily.
Adult outpatients (>40 years) with symptomatic hip osteoarthritis (Kellgren-Lawrence II-III) receiving intra-articular hyaluronic acid.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patients with hip osteoarthritis treated with HA under real-world clinical practice conditions
Change from Baseline in self-reported hip pain severityu as measured by Visual Analog Scale (VAS) Pain Score at 12 months
Assessment of patient-reported hip pain severity on a VAS, consisting of a 100mm horizontal line ranging from 0 mm (no pain) to 100 mm (worst imaginable pain). Higher scores indicate greater pain intensity; a negative change score reflects pain reduction.
Time frame: Baseline (pre-treatment), 3 months and 12 months post-treatment
Change from Baseline in hip osteoarthritis symptoms as measured by WOMAC Osteoarthritis Index Total Score
Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) evaluating hip pain, stiffness, and physical function. Total score ranges from 0 to 96 points, where higher scores indicate worse symptom severity and greater physical disability.
Time frame: Baseline, Month 3, and Month 12
Change from Baseline in hip joint function as measured by Modified Harris Hip Score (mHHS)
Clinician- and patient-assessed standardized scale evaluating hip joint pain, gait, daily activities, and range of motion. Total score ranges from 0 to 100 points, where higher scores indicate superior hip joint function.
Time frame: Baseline, Month 3, and Month 12
Change from Baseline in health-related quality of life as measured by the 12-Item Short Form Health Survey (SF-12)
Assessment of physical and mental health-related quality of life dimensions using the 12-Item Short Form Health Survey (SF-12). Standardized scores range from 0 to 100 points, where higher scores represent better health-related quality of life.
Time frame: Baseline and Month 12
Incidence and severity of Adverse Events (AEs) and Serious Adverse Events (SAEs)
Percentage of participants experiencing adverse events and serious adverse events related or unrelated to intra-articular hyaluronic acid treatment throughout the follow-up period.
Time frame: From baseline up to Month 12
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Meiji Pharma Spain S.A.